PL3562821T3 - Związki izochinolinowe, sposoby ich wytwarzania i ich zastosowania terapeutyczne w stanach związanych ze zmianą aktywności beta-galaktozydaz - Google Patents
Związki izochinolinowe, sposoby ich wytwarzania i ich zastosowania terapeutyczne w stanach związanych ze zmianą aktywności beta-galaktozydazInfo
- Publication number
- PL3562821T3 PL3562821T3 PL17829043T PL17829043T PL3562821T3 PL 3562821 T3 PL3562821 T3 PL 3562821T3 PL 17829043 T PL17829043 T PL 17829043T PL 17829043 T PL17829043 T PL 17829043T PL 3562821 T3 PL3562821 T3 PL 3562821T3
- Authority
- PL
- Poland
- Prior art keywords
- alteration
- activity
- preparation
- methods
- conditions associated
- Prior art date
Links
- 230000004075 alteration Effects 0.000 title 1
- 102000005936 beta-Galactosidase Human genes 0.000 title 1
- 108010005774 beta-Galactosidase Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382660 | 2016-12-28 | ||
| PCT/IB2017/058438 WO2018122746A1 (en) | 2016-12-28 | 2017-12-27 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
| EP17829043.3A EP3562821B9 (en) | 2016-12-28 | 2017-12-27 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3562821T3 true PL3562821T3 (pl) | 2021-06-14 |
Family
ID=57777485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17829043T PL3562821T3 (pl) | 2016-12-28 | 2017-12-27 | Związki izochinolinowe, sposoby ich wytwarzania i ich zastosowania terapeutyczne w stanach związanych ze zmianą aktywności beta-galaktozydaz |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11440898B2 (https=) |
| EP (1) | EP3562821B9 (https=) |
| JP (1) | JP7144863B2 (https=) |
| CN (1) | CN110494432B (https=) |
| AU (1) | AU2017388300B2 (https=) |
| BR (1) | BR112019013593A2 (https=) |
| CA (1) | CA3047700A1 (https=) |
| DK (1) | DK3562821T3 (https=) |
| ES (1) | ES2862374T3 (https=) |
| IL (1) | IL267553B (https=) |
| PL (1) | PL3562821T3 (https=) |
| PT (1) | PT3562821T (https=) |
| WO (1) | WO2018122746A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023042177A1 (en) | 2021-09-20 | 2023-03-23 | Gt Gain Therapeutics Sa | Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide |
| WO2025094117A1 (en) * | 2023-11-02 | 2025-05-08 | Gt Gain Therapeutics Sa | Substituted indolyl compounds, compositions thereof, and therapeutic uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526560D0 (en) | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
| DE19740785A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Arylsulfonamide und Analoga |
| YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| PT1254138E (pt) | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
| WO2003022797A1 (en) | 2001-09-07 | 2003-03-20 | Seikagaku Corporation | Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient |
| US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| WO2004078114A2 (en) | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists. |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| CA2553969A1 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP2007526324A (ja) | 2004-03-02 | 2007-09-13 | スミスクライン・ビーチャム・コーポレイション | Ａｋｔ活性のある阻害剤 |
| US20050250820A1 (en) | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
| TW200628463A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| WO2006058201A2 (en) | 2004-11-23 | 2006-06-01 | Reddy Us Therapeutics, Inc. | Heterocyclic and bicyclic compounds, compositions and methods |
| KR20070094754A (ko) | 2004-12-01 | 2007-09-21 | 데브젠 엔브이 | 이온 채널, 특히 Ｋｖ 패밀리로부터의 이온 채널과상호작용하는 5-카복사미도 치환된 티아졸 유도체 |
| DK1838674T3 (da) | 2005-01-14 | 2011-06-14 | Chemocentryx Inc | Heteroarylsulfonamider og CCR2 |
| AT502145B1 (de) | 2005-03-24 | 2012-01-15 | Univ Graz Tech | Glycosidase-hemmendes iminoalditol |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| MX2008005814A (es) | 2005-11-03 | 2008-10-15 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
| US20070179125A1 (en) | 2005-11-16 | 2007-08-02 | Damien Fraysse | Aminopyrimidines useful as kinase inhibitors |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| CA2660421A1 (en) | 2006-08-10 | 2008-02-14 | Ferrer Internacional S.A. | 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions |
| EP1903034A1 (en) | 2006-09-19 | 2008-03-26 | Technische Universität Graz | Iminosugar glycoconjugates |
| WO2009042294A2 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| WO2009049421A1 (en) | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease |
| SI2217572T1 (sl) | 2007-11-16 | 2014-05-30 | Vertex Pharmaceuticals Incorporated | Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto |
| ES2337435B8 (es) | 2008-10-22 | 2011-07-19 | Consejo Superior De Investigaciones Cientificas (Csic) (25%) | Compuestos potenciadores de la actividad de glicosidasas mutantes. |
| US8546405B2 (en) | 2008-12-23 | 2013-10-01 | Abbott Laboratories | Anti-viral compounds |
| SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| SI2995306T1 (sl) | 2009-10-19 | 2019-04-30 | Amicus Therapeutics, Inc. | Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| KR101987736B1 (ko) | 2011-03-18 | 2019-06-11 | 젠자임 코포레이션 | 글루코실세라마이드 합성효소 억제제 |
| WO2013005168A2 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Cannabinoid receptor modulators |
| BR112014015720B1 (pt) | 2011-12-30 | 2020-03-17 | Hanmi Pharm. Co., Ltd. | Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase |
| RU2015113597A (ru) * | 2012-09-14 | 2016-11-10 | Итернити Байосайенс Инк. | Производные аминоизохинолина в качестве ингибиторов протеинкиназы |
| WO2014120995A2 (en) | 2013-02-01 | 2014-08-07 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
| WO2015014900A1 (en) * | 2013-07-31 | 2015-02-05 | Minoryx Therapeutics S.L. | Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof |
| AU2014347027A1 (en) | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | GSK -3 inhibitors |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| AU2015249497A1 (en) | 2014-04-25 | 2016-10-20 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| WO2016120808A1 (en) * | 2015-01-28 | 2016-08-04 | Minoryx Therapeutics S.L. | Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof |
-
2017
- 2017-12-27 WO PCT/IB2017/058438 patent/WO2018122746A1/en not_active Ceased
- 2017-12-27 EP EP17829043.3A patent/EP3562821B9/en active Active
- 2017-12-27 JP JP2019535381A patent/JP7144863B2/ja active Active
- 2017-12-27 BR BR112019013593-6A patent/BR112019013593A2/pt not_active IP Right Cessation
- 2017-12-27 CN CN201780086786.5A patent/CN110494432B/zh not_active Expired - Fee Related
- 2017-12-27 CA CA3047700A patent/CA3047700A1/en active Pending
- 2017-12-27 DK DK17829043.3T patent/DK3562821T3/da active
- 2017-12-27 PT PT178290433T patent/PT3562821T/pt unknown
- 2017-12-27 PL PL17829043T patent/PL3562821T3/pl unknown
- 2017-12-27 US US16/473,966 patent/US11440898B2/en active Active
- 2017-12-27 AU AU2017388300A patent/AU2017388300B2/en not_active Ceased
- 2017-12-27 ES ES17829043T patent/ES2862374T3/es active Active
-
2019
- 2019-06-20 IL IL267553A patent/IL267553B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL267553B (en) | 2021-10-31 |
| CN110494432B (zh) | 2022-08-12 |
| JP7144863B2 (ja) | 2022-09-30 |
| JP2020514284A (ja) | 2020-05-21 |
| CN110494432A (zh) | 2019-11-22 |
| EP3562821B1 (en) | 2020-12-02 |
| BR112019013593A2 (pt) | 2020-01-07 |
| IL267553A (en) | 2019-08-29 |
| DK3562821T3 (da) | 2021-02-15 |
| US11440898B2 (en) | 2022-09-13 |
| CA3047700A1 (en) | 2018-07-05 |
| ES2862374T3 (es) | 2021-10-07 |
| EP3562821B9 (en) | 2021-05-26 |
| PT3562821T (pt) | 2021-03-03 |
| EP3562821A1 (en) | 2019-11-06 |
| WO2018122746A1 (en) | 2018-07-05 |
| AU2017388300B2 (en) | 2022-03-31 |
| AU2017388300A1 (en) | 2019-07-11 |
| US20200071294A1 (en) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269444B (en) | New modified indazoles, methods for their production, pharmaceutical preparations containing the new modified indazoles, and the use of the new modified indazoles in the production of drugs | |
| HUE057285T2 (hu) | Terápiás ellenanyagok és alkalmazásaik | |
| SG10201914111XA (en) | 5-substituted indazole-3-carboxamides and preparation and use thereof | |
| EP3282896A4 (en) | Special effect chair and system including the same | |
| GB201519128D0 (en) | Solid forms and methods of preparing the same | |
| IL258005A (en) | Methods and materials for gene therapy for beta-4,1-en.-acetylgalactosaminyltransferase 2 | |
| EP3250589A4 (en) | Therapeutic and diagnostic agents | |
| GB201513098D0 (en) | Catalytically active protein aggregates and methods for producing the same | |
| EP3302530A4 (en) | Cdh26 based therapeutic agents and their use | |
| SG11201609948YA (en) | Lobaplatin crystal, preparation method and pharmaceutical application | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| IL267553B (en) | Iso-quinone compounds, methods for their preparation and their medical uses in conditions related to a change in the activity of beta-galactosidase | |
| PT3350150T (pt) | 1,1-difeniletilenos substituídos por alcenilfenoxilo, processos para a sua preparação e sua utilização | |
| GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
| PL3541911T3 (pl) | Preparaty, ich wytwarzanie i zastosowanie | |
| PT3177596T (pt) | Processo melhorado para a preparação de eslicarbazepina e acetato de eslicarbazepina | |
| EP3253318A4 (en) | Thermal therapy systems and methods | |
| PL3407890T3 (pl) | Preparat farmaceutyczny i jego zastosowanie w leczeniu wirusowego zapalenia krtani | |
| ZA201607353B (en) | Bicyclic derivatives and pharmaceutical composition including the same | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| ZA201505621B (en) | Carbodithioates with spermicidal activity and process for preparation thereof | |
| PL3070078T3 (pl) | Niesymetryczne bisakrydyny o działaniu przeciwnowotworowym i ich zastosowania | |
| IL251930B (en) | Benzylhydroxy derivatives, their preparation and medical uses | |
| HUE056121T2 (hu) | Kompozíció UV-B terápia hatékonyságának növelésére, eljárás annak elõállítására, és alkalmazása | |
| AU2015900260A0 (en) | Therapeutic and diagnostic agents |